Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. (AIMLF) delivers cutting-edge artificial intelligence and machine learning solutions for digital health transformation. This page provides investors and industry professionals with essential updates about the company's strategic initiatives, regulatory milestones, and technological advancements.
Access comprehensive coverage of AIMLF's partnerships with Health Gauge Inc., AI Rx Inc., and other key players in healthcare technology. Track developments stemming from acquisitions like Quantum Sciences Ltd. and stay informed about operational updates across neural networks, cloud computing integrations, and precision healthcare platforms.
Key updates include: earnings reports, strategic investment announcements, regulatory filings, and leadership changes. Our curated news collection ensures you receive accurate information about the company's progress in developing AI-powered diagnostic tools and patient engagement systems.
Bookmark this page for verified updates about AIMLF's role in advancing machine learning applications for cardiovascular monitoring, neurodegenerative disorder management, and metabolic health solutions. Visit regularly to maintain current awareness of this innovator's evolving position in digital healthcare markets.
AI/ML Innovations Inc. (AIMLF) has announced a non-brokered private placement offering of up to 40 million units at $0.05 per unit, aiming to raise gross proceeds of up to $2 million.
Each unit consists of one common share and one warrant. The warrants have a 2-year term and allow holders to purchase one common share at $0.15, with an acceleration clause if shares trade at $0.30 for 10 days. The securities will have a four-month and one-day hold period.
The company plans to use the net proceeds for working capital requirements. Finder's fees will be paid to qualified finders in cash, securities, or both. The private placement requires approval from the Canadian Securities Exchange.
AI/ML Innovations Inc. (AIML) has announced its strategic exit from Tech2Heal SAS (T2H) through a formal agreement dated March 21, 2025. This decision follows a previously reported impairment loss of $1,510,668 from their T2H investment in October 2024.
Under the exit agreement, AIML will relinquish its 11.11% equity position in T2H, board seat rights, and AI RX Inc.'s exclusive North American product rights. In exchange, T2H will return 1,500,000 AIML common shares for cancellation and surrender its 30% equity in AI RX Inc. Additionally, T2H's CEO Fabrice Pakin will step down from both AIML and AI RX Inc.'s boards.
The company will now focus on commercializing its core holdings: NeuralCloud Solutions Inc., Health Gauge Inc. (95.2% owned), and Quantum Sciences . This restructuring aims to optimize the utilization of AIML's human, financial, and technological resources while remaining open to future collaborations with T2H.
AI/ML Innovations Inc. (AIML) has announced significant leadership changes to drive growth and commercialization. Paul Duffy, the company's CEO, has been appointed Executive Chairman of the Board, while Peter Kendall, President and Chief Commercialization Officer, joins as a new board member. Former Executive Chair Mark Orsmond and board member Michael Nemirow have transitioned to strategic advisor roles.
These changes align with AIML's strategic focus on commercial execution, market penetration, and strategic partnerships in AI-driven healthcare technologies. Orsmond and Nemirow will continue supporting corporate development initiatives, strategic partnerships, and commercialization strategies in their advisory capacities.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) held its Annual General and Special Meeting where shareholders voted on key matters. A total of 54,405,656 shares (31.48% of outstanding shares) were represented. Shareholders approved the following resolutions:
- Fixed the number of directors at four
- Elected Tim Daniels, Mark Orsmond, Michael Nemirow, and Drew Dundas as directors
- Reappointed Baker Tilly WM LLP as auditor
- Approved the Company's Stock Option Plan and RSU/DSU Plan
The company focuses on artificial intelligence and machine learning in digital health through various subsidiaries and partnerships: Quantum Sciences (100% owned), NeuralCloud Solutions (100% owned), Health Gauge (95.2% owned), Tech2Heal (11.11% owned), and AI Rx (70% owned).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced key updates to its upcoming annual general and special meeting scheduled for February 21, 2025. The company plans to increase its board seats from three to four and has nominated Dr. Drew Dundas to fill the additional position.
Dr. Dundas brings over 20 years of technology and research leadership experience, currently serving as Chief Technology Officer at Earlens His extensive background includes roles as President and CTO of Soundhawk , Director of Audiology at UCSF Medical Center, and research contributions at Starkey Hearing Technologies. He holds a PhD in Audiology & Biomedical Engineering from Vanderbilt University.
AIML focuses on artificial intelligence and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge (95.2% owned), Tech2Heal (11.11% owned), and AI Rx (70% owned).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Andrea L. Ruth as Head of Quality, Clinical, and Regulatory Affairs. With over 20 years of experience in medical device and biotechnology sectors, Ruth brings expertise in regulatory compliance and quality systems implementation.
Ruth, who holds a Master of Management, has extensive experience working with global regulatory bodies including FDA and EMA. Her role will focus on maintaining safety, efficacy, and compliance standards as AIML expands its AI-driven healthcare solutions portfolio.
AIML operates in artificial intelligence and machine learning fields, focusing on digital health and wellbeing solutions. The company owns Quantum Sciences , NeuralCloud Solutions Inc., and has strategic partnerships with Health Gauge Inc. (95.2% owned), Tech2Heal (11.11% owned), and AI Rx Inc. (70% owned).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships. Dr. Rabinowitz brings over two decades of experience in clinical cardiology and healthcare strategy, currently serving as Clinical Associate Professor in Cardiology at UBC and previously as Director of the Coronary Care Unit at St. Paul's Hospital.
Dr. Rabinowitz's expertise spans entrepreneurial ventures in advanced diagnostics and personalized medicine, with a focus on integrating artificial intelligence in cardiology. He holds a medical degree from the University of Cape Town, with specializations from the University of Toronto and UBC.
The company also announced a stock option grant of 400,000 shares at $0.105 per share to an officer, vesting quarterly over two years. AIML focuses on AI and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal, and AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced significant changes to its Board of Directors. Mark Orsmond, a veteran healthcare executive with over 30 years of experience, has been appointed as Executive Chair. Orsmond's track record includes successfully developing and selling three healthcare businesses to Well Health Technologies Corp., and serving as CFO and Executive VP at Corix Group and ALL-SEA Group.
Michael Nemirow joins as Director, bringing extensive entrepreneurial experience, notably as CEO of Greenstar Plant Products, which he led to global expansion before its acquisition by a U.S. public company in 2021. The company has also granted stock options to a director for 250,000 shares at $0.17 per share, vesting quarterly over one year.
Tim Daniels will step down as Executive Chairman but remain on the Board. These appointments align with AIML's focus on AI and machine learning in digital health and wellbeing solutions.
AI/ML Innovations Inc. (AIML) has appointed Peter Kendall as President and Chief Commercialization Officer, effective January 6, 2025. Kendall, with extensive experience at TELUS Health, Medisys, Lifemark, and 3M, brings expertise in revenue generation and strategic planning across Canada, US, and Europe.
The appointment includes a compensation package featuring a $120,000 signing bonus payable in company shares ($60,000 at appointment and $60,000 after two years), with shares issued at $0.145 or fair market value (minimum $0.05). Additionally, Kendall received 2.5 million stock options at $0.145 per share, vesting in three installments over 12 months.
AIML focuses on AI and machine learning in digital health, owning Quantum Sciences , NeuralCloud Solutions Inc., and holding majority stakes in Health Gauge (70%), AI Rx Inc. (70%), and a 22% commitment in Tech2Heal.
AI/ML Innovations (AIMLF) has completed the acquisition of Quantum Sciences , a company specializing in AI-driven digital healthcare solutions. The acquisition, valued at $750,000, was executed through the issuance of 10 million company shares at $0.075 per share.
Quantum's focus includes developing technologies for cardiovascular disease, neurodegenerative disorders, and metabolic conditions. The company has spent two years designing software to improve patient health management through a centralized information system.
The acquisition brings together AI/ML's signal processing capabilities with Quantum's experienced medical team, including notable cardiologists Dr. Alan Rabinowitz, Dr. Marc W. Deyell, and Dr. Brett Heilbron from St. Paul's Hospital. The shares issued are subject to trading restrictions and voluntary escrow conditions.
FAQ
What is the current stock price of AI / ML Innovations (AIMLF)?
What is the market cap of AI / ML Innovations (AIMLF)?
